These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 30505257)
1. Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II. Oh S; Kim JS; Oh YS; Shin DG; Pak HN; Hwang GS; Choi KJ; Kim JB; Lee MY; Park HW; Kim DK; Jin ES; Park J; Oh IY; Shin DH; Park HS; Kim JH; Kim NH; Ahn MS; Seo BJ; Kim YJ; Kang S; Lee J; Kim YH J Korean Med Sci; 2018 Dec; 33(49):e323. PubMed ID: 30505257 [TBL] [Abstract][Full Text] [Related]
2. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland. Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622 [TBL] [Abstract][Full Text] [Related]
3. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073 [TBL] [Abstract][Full Text] [Related]
4. Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. Bae HJ; Heo JH; Jung KH; Lee YS; Hong KS; Seo WK; Koo J; Cha JK; Lee MJ; Seo BJ; Kim YJ; Kang S; Seok J; Lee J; Chung CS PLoS One; 2018; 13(11):e0202803. PubMed ID: 30388109 [TBL] [Abstract][Full Text] [Related]
5. Vitamin K antagonists in patients with nonvalvular atrial fibrillation: appropriateness and quality of treatment in an Italian cohort. Pereira de Sousa L; Burba I; Ruperto C; Lattuada L; Barbone F; Di Chiara A J Cardiovasc Med (Hagerstown); 2013 Jul; 14(7):534-40. PubMed ID: 23328227 [TBL] [Abstract][Full Text] [Related]
6. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study. García-Sempere A; Hurtado I; Bejarano-Quisoboni D; Rodríguez-Bernal C; Santa-Ana Y; Peiró S; Sanfélix-Gimeno G PLoS One; 2019; 14(2):e0211681. PubMed ID: 30753227 [TBL] [Abstract][Full Text] [Related]
7. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina. Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M; Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542 [TBL] [Abstract][Full Text] [Related]
8. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115 [TBL] [Abstract][Full Text] [Related]
9. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK; PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741 [TBL] [Abstract][Full Text] [Related]
10. Real-life cost of vitamin K antagonist treatment in patients with non-valvular atrial fibrillation in France in 2013. Dallongeville J; Ansolabehere X; Karusisi N; Maurel F; Van Ganse E; Le Heuzey JY J Med Econ; 2017 Sep; 20(9):974-981. PubMed ID: 28682153 [TBL] [Abstract][Full Text] [Related]
11. Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study. Lee YS; Oh YS; Choi EK; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D Open Heart; 2021 Dec; 8(2):. PubMed ID: 34857666 [TBL] [Abstract][Full Text] [Related]
12. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973 [TBL] [Abstract][Full Text] [Related]
13. Impact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study. Biedermann JS; van Rein N; van den Besselaar AM; Buhre PN; de Maat MP; van der Meer FJ; Leebeek FW; Kruip MJ J Thromb Haemost; 2016 Apr; 14(4):695-703. PubMed ID: 26806724 [TBL] [Abstract][Full Text] [Related]
14. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes. Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326 [TBL] [Abstract][Full Text] [Related]
15. The rs2108622 polymorphism is related to the early risk of ischemic stroke in non-valvular atrial fibrillation subjects under oral anticoagulation. Colàs-Campàs L; Royo JL; Montserrat MV; Marzo C; Molina-Seguín J; Benabdelhak I; Cambray S; Purroy F Pharmacogenomics J; 2018 Sep; 18(5):652-656. PubMed ID: 29273767 [TBL] [Abstract][Full Text] [Related]
16. Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. Zulkifly H; Cheli P; Lutchman I; Bai Y; Lip GYH; Lane DA Thromb Res; 2020 Aug; 192():12-20. PubMed ID: 32416364 [TBL] [Abstract][Full Text] [Related]
17. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control. Bonde AN; Staerk L; Lee CJ; Vinding NE; Bang CN; Torp-Pedersen C; Gislason G; Lip GYH; Olesen JB J Am Coll Cardiol; 2018 Sep; 72(12):1357-1365. PubMed ID: 30213328 [TBL] [Abstract][Full Text] [Related]
18. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends. Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389 [TBL] [Abstract][Full Text] [Related]
19. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study. Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558 [TBL] [Abstract][Full Text] [Related]
20. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]